Implications of Five Different Risk Models In Primary Prevention Guidelines.

IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Maneesh Sud, Atul Sivaswamy, Peter C Austin, Husam Abdel-Qadir, Todd J Anderson, David M J Naimark, Douglas S Lee, Idan Roifman, George Thanassoulis, Karen Tu, Harindra C Wijeysundera, Dennis T Ko
{"title":"Implications of Five Different Risk Models In Primary Prevention Guidelines.","authors":"Maneesh Sud, Atul Sivaswamy, Peter C Austin, Husam Abdel-Qadir, Todd J Anderson, David M J Naimark, Douglas S Lee, Idan Roifman, George Thanassoulis, Karen Tu, Harindra C Wijeysundera, Dennis T Ko","doi":"10.1093/ehjqcco/qcae034","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A lack of consensus exists across guidelines as to which risk model should be used for the primary prevention of cardiovascular disease (CVD). Our objective was to determine potential improvements in the number needed to treat (NNT) and number of events prevented (NEP) using different risk models in patients eligible for risk stratification.</p><p><strong>Methods: </strong>A retrospective observational cohort was assembled from primary care patients in Ontario, Canada between January 1st, 2010, to December 31st, 2014 and followed for up to 5 years. Risk estimation was undertaken in patients 40-75 years of age, without CVD, diabetes, or chronic kidney disease using the Framingham Risk Score (FRS), Pooled Cohort Equations (PCEs), a recalibrated FRS (R-FRS), Systematic Coronary Risk Evaluation 2 (SCORE2), and the low-risk region recalibrated SCORE2 (LR-SCORE2).</p><p><strong>Results: </strong>The cohort consisted of 47,399 patients (59% women, mean age 54). The NNT with statins was lowest for SCORE2 at 40, followed by LR-SCORE2 at 41, R-FRS at 43, PCEs at 55, and FRS at 65. Models that selected for individuals with a lower NNT recommended statins to fewer, but higher risk patients. For instance, SCORE2 recommended statins to 7.9% of patients (5-year CVD incidence 5.92%). The FRS, however, recommended statins to 34.6% of patients (5-year CVD incidence 4.01%). Accordingly, the NEP was highest for the FRS at 406 and lowest for SCORE2 at 156.</p><p><strong>Conclusions: </strong>Newer models such as SCORE2 may improve statin allocation to higher risk groups with a lower NNT but prevent fewer events at the population level.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Quality of Care and Clinical Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcae034","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A lack of consensus exists across guidelines as to which risk model should be used for the primary prevention of cardiovascular disease (CVD). Our objective was to determine potential improvements in the number needed to treat (NNT) and number of events prevented (NEP) using different risk models in patients eligible for risk stratification.

Methods: A retrospective observational cohort was assembled from primary care patients in Ontario, Canada between January 1st, 2010, to December 31st, 2014 and followed for up to 5 years. Risk estimation was undertaken in patients 40-75 years of age, without CVD, diabetes, or chronic kidney disease using the Framingham Risk Score (FRS), Pooled Cohort Equations (PCEs), a recalibrated FRS (R-FRS), Systematic Coronary Risk Evaluation 2 (SCORE2), and the low-risk region recalibrated SCORE2 (LR-SCORE2).

Results: The cohort consisted of 47,399 patients (59% women, mean age 54). The NNT with statins was lowest for SCORE2 at 40, followed by LR-SCORE2 at 41, R-FRS at 43, PCEs at 55, and FRS at 65. Models that selected for individuals with a lower NNT recommended statins to fewer, but higher risk patients. For instance, SCORE2 recommended statins to 7.9% of patients (5-year CVD incidence 5.92%). The FRS, however, recommended statins to 34.6% of patients (5-year CVD incidence 4.01%). Accordingly, the NEP was highest for the FRS at 406 and lowest for SCORE2 at 156.

Conclusions: Newer models such as SCORE2 may improve statin allocation to higher risk groups with a lower NNT but prevent fewer events at the population level.

五种不同风险模型对初级预防指南的影响。
背景:关于心血管疾病(CVD)一级预防应采用哪种风险模型,各指南之间缺乏共识。我们的目的是确定在符合风险分层条件的患者中使用不同的风险模型对治疗所需人数(NNT)和预防事件数(NEP)的潜在改进:从 2010 年 1 月 1 日至 2014 年 12 月 31 日期间,从加拿大安大略省的初级保健患者中收集了一个回顾性观察队列,并进行了长达 5 年的随访。使用弗雷明汉风险评分(Framingham Risk Score,FRS)、集合队列方程(Pooled Cohort Equations,PCEs)、重新校准的FRS(R-FRS)、系统冠状动脉风险评估2(Systematic Coronary Risk Evaluation 2,SCORE2)和低风险地区重新校准的SCORE2(LR-SCORE2)对40-75岁、无心血管疾病、糖尿病或慢性肾病的患者进行风险评估:队列中有 47399 名患者(59% 为女性,平均年龄 54 岁)。使用他汀类药物的 NNT 最低的是 SCORE2,为 40;其次是 LR-SCORE2,为 41;R-FRS,为 43;PCEs,为 55;FRS,为 65。选择 NNT 较低个体的模型向较少但风险较高的患者推荐他汀类药物。例如,SCORE2 向 7.9% 的患者推荐他汀类药物(5 年心血管疾病发病率为 5.92%)。而 FRS 则向 34.6% 的患者推荐他汀类药物(5 年心血管疾病发病率为 4.01%)。因此,FRS 的 NEP 最高,为 406,SCORE2 最低,为 156.结论:结论:SCORE2 等新模型可改善高风险人群的他汀类药物分配,其 NNT 值较低,但在人群水平上可预防的事件较少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.40
自引率
3.80%
发文量
76
期刊介绍: European Heart Journal - Quality of Care & Clinical Outcomes is an English language, peer-reviewed journal dedicated to publishing cardiovascular outcomes research. It serves as an official journal of the European Society of Cardiology and maintains a close alliance with the European Heart Health Institute. The journal disseminates original research and topical reviews contributed by health scientists globally, with a focus on the quality of care and its impact on cardiovascular outcomes at the hospital, national, and international levels. It provides a platform for presenting the most outstanding cardiovascular outcomes research to influence cardiovascular public health policy on a global scale. Additionally, the journal aims to motivate young investigators and foster the growth of the outcomes research community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信